Melanoma, Breast Cancer, Brain Cancer, Non-small Cell Lung Cancer
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma that has Spread to the Brain
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
Your participation could last approximately 5 months depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have brain metastases secondary to HER2+ or HER2- breast cancer, NSCLC, or melanoma
Participant must have a life expectancy ≥12 weeks
Participant must not be taking concurrent enzyme-inducing antiepileptic drugs (EIAED)
Participant must not have had >2 seizures within 4 weeks prior to study entry
Participant must not have previously received treatment with any cyclin dependent kinase 6 (CDK6) inhibitor